Autoradiographic Evaluation of [11 C] Vinpocetine Binding in the Human Postmortem Brain


The main objective of the study was to evaluate with autoradiographic technique whether or not [11C]vin-pocetine, a compound widely used in the prevention and treatment of cerebrovascular diseases (Cavinton®, Gedeon Richter Ltd., Budapest), binds to specific sites in the human brain in post mortem human brain sections. Binding was assessed under four conditions: the incubation was performed using Tris-HCl buffer with or without the addition of salts (0.1% (weight/vol) ascorbic acid, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2 and 1 mM MgCl2), with or without the addition of excess (10 µM) unlabelled vinpocetine. Measurements on digitized autoradiograms indicated that [11C]vinpocetine labelled all grey matter areas in the human brain to a similar extent and no significantly heterogeneous binding could be demonstrated among cortical or subcortical regions. The addition of excess unlabelled vinpocetine lowered the binding slightly in all regions. Although these results indicate that [11C]vinpocetine does not bind to human brain transmitter receptors or transporters with a high affinity (Ki < 10 nM), it cannot be ruled out that the compound binds to receptors and/or transporters with lower affinity.


  1. 1.

    Beavo, J. A. (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple iso-forms. Physiol. Rev. 75, 725–748.

    CAS  Article  Google Scholar 

  2. 2.

    Bönöczk, P., Gulyás, B., Ádám-Vizi, V., Nemes, A., Kárpáti, E., Kiss, B., Kapás, M., Szántay, C., Koncz, I., Zelles, T., Vas, Á. (2000) Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 53, 245–254.

    Article  Google Scholar 

  3. 3.

    Culmsee, C., Semkova, I., Krieglstein, J. (1999) NGF mediates the neuroprotective effect of the beta2-adrenoceptor agonist clenbuterol in vitro and in vivo: evidence from an NGF-antisense study. Neurochem. Int. 35, 47–57.

    CAS  Article  Google Scholar 

  4. 4.

    Gulyás, B., Csiba, L., Kerényi, L., Galuska, L., Trón, L. (1998) The effect of a single-dose intravenous vinpocetine on chronic stroke patients. A PET study. In: B. Gulyás and H. W. Müller-Gärtner (eds). Positron Emission Tomography: A Critical Assessment of Recent Trends. Kluwer Academic Publishers, Dordrecht, pp. 291–306.

    Google Scholar 

  5. 5.

    Gulyás, B., Halldin, C., Karlsson, P., Chou, Y.-H., Swahn, C.-G., Farde, L. (1999) Brain uptake and plasma metabolism of 11C-vinpocetine. A PET-study in cynomolgus monkey. J. Neuroimaging, 9, 217–222.

    Article  Google Scholar 

  6. 6.

    Hall, H., Farde, L., Sedvall, G. (1988) Human dopamine receptor subtypes k]in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride. J. Neur. Transm. 73, 7–21.

    CAS  Article  Google Scholar 

  7. 7.

    Hall, H., Halldin, C., Farde, L., Sedvall, G. (1998) Whole hemisphere autoradiography of the postmortem human brain. Nucl. Med. Biol. 25, 715–719.

    CAS  Article  Google Scholar 

  8. 8.

    Hall, H., Hurd, Y., Pauli, S., Halldin, C., Sedvall, G. (2001) Human brain imaging post-mortem k]whole hemisphere technologies. Int. Rev. Psych. 13, 12–17.

    CAS  Article  Google Scholar 

  9. 9.

    Hall, H., Sedvall, G., Magnusson, O., Kopp, J., Halldin, C., Farde, L. (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsycho-pharmacology 11, 245–256.

    CAS  Article  Google Scholar 

  10. 10.

    Halldin, C., Farde, L., Högberg, T., Hall, H., Sedvall, G. (1990) 11 C-Labelling of eticlopride in two different positions k]a selective high affinity ligand for the study of dopamine D-2 receptors using PET. Appl. Radiat. Isot. 19, 669–674.

    Article  Google Scholar 

  11. 11.

    Hara, H., Ozaki, A., Yoshidomi, M. S. T. (1990) Protective effect of KB-2796, a new calcium antagonist, in cerebral hypoxia and ischemia. Arch. Int. Pharmacodyn. Ther. 304, 206–218.

    CAS  PubMed  Google Scholar 

  12. 12.

    Hidaka, H. (1984) Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases. Trends Pharm. Sci. 5, 1–3.

    Article  Google Scholar 

  13. 13.

    Hortobágyi, T., Harkány, T., Reisch, R., Urbanics, R., Kálmán, M., Nyakas, C., Nagy, Z. (1998) Neurotrophin-mediated neuroprotection by solid fetal telencephalic graft in middle cerebral artery occlusion: a preventive approach. Brain Res. Bull. 47, 185–191.

    Article  Google Scholar 

  14. 14.

    Kaneko, S., Takahashi, H., Satoh, M. (1990) The use o. Xenopus oocytes to evaluate drugs affecting brain Ca2+ channels: effects of bifemelane and several nootropic agents. Eur. J. Pharmacol. 189, 51–58.

    CAS  Article  Google Scholar 

  15. 15.

    Kiss, B., Cai, N. S., Erdő, S. L. (1991) Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies. Eur. J. Pharmacol. 209, 109–112.

    CAS  Article  Google Scholar 

  16. 16.

    Lamar, J. C., Beaughard, M., Bromont, C., Pignet, H. (1986) Effects of vinpocetine in four pharmacological models of cerebral ischaemia. In: Krieglstein, J. (ed.). Pharmacology of Cerebral Ischemia. Elsevier, Amsterdam, pp. 334–339.

    Google Scholar 

  17. 17.

    Lim, C. C., Cook, P. J., James, I. M. (1980) The effect of an acute infusion of vincamine and ethyl apovincaminate on cerebral blood flow in healthy volunteers. Br. J. Clin. Pharmacol. 9, 100–101.

    CAS  Article  Google Scholar 

  18. 18.

    Miyazaki, M. (1995) The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology 46, 53–58.

    CAS  Article  Google Scholar 

  19. 19.

    Nakazawa, M., Matsuno, K., Mita, S. (1998) Activation of sigma1 receptor subtype leads to neuroprotection in the rat primary neuronal cultures. Neurochem. Int. 32, 337–343.

    CAS  Article  Google Scholar 

  20. 20.

    Nicholson, C. D. (1990) Pharmacology of nootropics and metabolically active compunds in relation to their use in dementia. Psychopharmacology (Berlin) 101, 147–159.

    CAS  Article  Google Scholar 

  21. 21.

    Persson, A., d’Argy, R., Gillberg, P. G., Halldin, C., Litton, J. E., Swahn, C. G., Sedvall, G. (1991) Autoradiography with saturation experiments of 11 C-Ro 15-1788 binding to human brain sections. J. Neurosci. Methods 36, 53–61.

    CAS  Article  Google Scholar 

  22. 22.

    Rischke, R., Krieglstein, J. (1990) Effects of vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischemia in the rat. Pharmacology 41, 153–160.

    CAS  Article  Google Scholar 

  23. 23.

    Salamon, G. (1971). Atlas de la Vascularisation Arterielle du Cerveau chez l’Homme. Sandoz, Paris, p. 189.

    Google Scholar 

  24. 24.

    Santos, M. S., Duarte, A. I., Moreira, P. I., Oliveira, C. R. (2000) Synaptosomal response to oxida-tive stress: effect of vinpocetine. Free Radic. Res. 32, 57–66.

    CAS  Article  Google Scholar 

  25. 25.

    Sauer, D., Rischke, R., Beck, T., Rossberg, C., Mennel, H. D., Bielenberg, G. W., Krieglstein, J. (1988) Vinpocetine prevents ischemic cell damage in rat hippocampus. Life Sci. 43, 1733–1739.

    CAS  Article  Google Scholar 

  26. 26.

    Stolc, S. (1999) Indole derivatives as neuroprotectants. Life Sci. 65, 1943–1950.

    CAS  Article  Google Scholar 

  27. 27.

    Szakáll, S., Boros, I., Balkay, L. Emri, M., Fekete, I., Kerényi, L., Lehel, S., Márián, T., Molnár, T., Varga, J., Galuska, L., Trón, L., Bereczki, D., Csiba, L., Gulyás, B. (1998) The cerebral effects of a single dose intravenous vinpocetine in chronic stroke patients: A PET study. J. Neuroimaging. 8, 197–294.

    Article  Google Scholar 

  28. 28.

    Tretter, L., Ádám-Vizi, V. (1998) The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes. Neuroreport 9, 1849–1853.

    CAS  Article  Google Scholar 

  29. 29.

    Urenjak, J., Obrenovitch, T. P. (1996) Pharmacological modulation of voltage-gated Na+ channels: a rational and effective strategy against ischemic brain damage. Pharmacol. Rev. 48, 21–67.

    CAS  Google Scholar 

  30. 30.

    Yamaguchi, K., Yamada, S., Yoshida, M., Kyuki, K., Okuyama, S. (1993) Anti-anoxic effects of VA-045. J. Pharmacol. 61 (Suppl. 1), 184.

    Google Scholar 

Download references

Author information



Corresponding author

Correspondence to B. Gulyás.

Additional information

Dedicated to Professor József Hámori on the occasion of his 70th birthday.

Rights and permissions

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Cite this article

Hall, H., Varnäs, K., Sandell, J. et al. Autoradiographic Evaluation of [11 C] Vinpocetine Binding in the Human Postmortem Brain. BIOLOGIA FUTURA 53, 59–66 (2002).

Download citation


  • Human brain
  • vinpocetine
  • autoradiography
  • post mortem neuroimaging
  • receptor binding